Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.8% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price traded down 2.8% during mid-day trading on Wednesday . The stock traded as low as $13.25 and last traded at $13.25. 206,690 shares were traded during mid-day trading, a decline of 66% from the average session volume of 606,487 shares. The stock had previously closed at $13.63.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a report on Monday, February 10th. They issued a “sell” rating for the company.

Tonix Pharmaceuticals Stock Performance

The firm’s 50-day moving average is $19.65 and its 200 day moving average is $20.20. The stock has a market cap of $28.17 million, a PE ratio of 0.00 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Institutional Trading of Tonix Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of TNXP. Geode Capital Management LLC raised its position in Tonix Pharmaceuticals by 1,600.1% in the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after purchasing an additional 1,855,907 shares during the last quarter. Jane Street Group LLC raised its position in Tonix Pharmaceuticals by 5,932.3% in the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after purchasing an additional 1,635,119 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Tonix Pharmaceuticals in the 4th quarter valued at $526,000. Northern Trust Corp purchased a new stake in Tonix Pharmaceuticals in the 4th quarter valued at $162,000. Finally, PFG Investments LLC purchased a new position in Tonix Pharmaceuticals during the 4th quarter worth $72,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.